Leqvio (Inclisiran) Side Effects: Real User Reports, Women's Physiology, and What to Expect

What Real Users Are Saying About Leqvio: The Honest Picture

User-generated reviews of Leqvio are thinner than for daily oral drugs, and the reason makes sense: you receive the injection in a clinic, twice a year, so there is less daily friction to complain about online. Still, accounts surface on Reddit threads (particularly r/Cholesterol and r/FamilialHypercholesterolemia), Drugs.com, and PatientsLikeMe. Here is what the pattern looks like across those sources, followed by what clinical trial data actually measured.

The most consistent theme across forums is a split between people who call it "the easiest thing I've ever done for my cholesterol" and a smaller group frustrated by access barriers, insurance denials, and the fact that their LDL did not drop quite as far as the trials promised. Side-effect complaints are genuinely rare in these posts. That matters, but it also reflects a selection bias worth naming: people who tolerate a drug well rarely post about it.

The Selection-Bias Problem You Need to Know

Before reading any user quote as evidence, keep this in mind. Online review populations skew toward people with strong reactions, either very positive or very negative. A 2023 cross-sectional analysis of drug-review platforms found that online medication reviews substantially over-represent adverse events relative to clinical-trial incidence rates. For a twice-yearly drug like Leqvio, the sample of active online reviewers is also small compared with a statin or GLP-1, simply because far fewer prescriptions have been written. Interpret every forum account below as a signal to discuss with your prescriber, not as a reliable prevalence estimate.

What People Say on Reddit and Patient Forums

On r/Cholesterol, the most upvoted thread about inclisiran (approximately 200 comments as of late 2024) shows a majority of commenters reporting no side effects beyond a sore arm for one to two days. Representative comments include users with heterozygous familial hypercholesterolemia (HeFH) who had already tried statins and ezetimibe, now describing Leqvio as "anticlimactic in the best way." A smaller subset of posts describe fatigue in the first week after injection, though users in those threads frequently acknowledge concurrent illness or other medications as possible confounders.

One recurring frustration on Drugs.com reviews (average rating 3.8 out of 5 across 41 reviews as of January 2025, though this figure shifts monthly and should be verified) is that the drug "works on paper" (lab values drop) but the clinic-only administration creates scheduling friction. Several women reviewers specifically mention that their gynecologist and their cardiologist do not communicate well, leaving them uncertain whether Leqvio interacts with their hormonal contraceptives or menopausal hormone therapy.

WomanRx Clinical Note: That communication gap is a real and underreported problem. Inclisiran has no known pharmacokinetic interaction with combined hormonal contraceptives or menopausal estrogen therapy based on current data, but women in trials were not routinely stratified by hormonal status. Your cardiologist and your women's-health provider need to be in the same chart.

Does Leqvio Actually Work? The Trial Evidence

Yes, Leqvio produces a clinically meaningful LDL reduction. The clearest evidence comes from two Phase 3 trials, ORION-10 and ORION-11, published in the New England Journal of Medicine in 2020. ORION-10 enrolled 1,561 patients with atherosclerotic cardiovascular disease (ASCVD) in the United States; ORION-11 enrolled 1,617 patients in Europe and South Africa, including people with ASCVD or HeFH.

ORION-10 and ORION-11 Key Numbers

Across both trials, inclisiran produced a time-averaged LDL-C reduction of approximately 50% versus placebo at 510 days, with a between-group difference of roughly 50 mg/dL. That reduction was sustained with the twice-yearly dosing schedule. The proportion of patients reaching an LDL below 70 mg/dL (the guideline target for very-high-risk patients) was substantially higher in the inclisiran arm than placebo.

The ORION-9 trial, published in NEJM 2020, focused specifically on patients with HeFH and showed a mean LDL-C reduction of 39.7% from baseline at day 510 compared with placebo, with a similar safety profile.

What the Trials Did Not Show (Yet)

ORION-10 and ORION-11 were not powered to detect cardiovascular event reduction. That outcome is being studied in ORION-4, a 15,000-patient outcomes trial with results expected around 2026. The FDA approved inclisiran in December 2021 based on LDL-lowering as a surrogate endpoint, not on demonstrated reductions in heart attacks or strokes. This is standard practice for lipid-lowering drugs but is worth knowing: the drug lowers the number on your lab report convincingly; whether that translates to fewer cardiovascular events at the same magnitude as statins has not yet been proven in a dedicated outcomes trial for inclisiran specifically.

Side Effects: What Trials Measured vs. What Users Report

Injection-Site Reactions: The Most Common Complaint

In the pooled ORION-10 and ORION-11 data, injection-site adverse events occurred in 8.2% of inclisiran-treated patients versus 1.8% in the placebo group. These were almost all mild to moderate: redness, pain, bruising, or swelling at the injection site in the upper arm or thigh. No patient discontinued the trial because of an injection-site reaction. This closely matches what real users describe online: "My arm was sore for a day or two" is the most common complaint in forum threads, with very few people calling it severe.

Systemic Side Effects: Rare but Reported

Systemic adverse-event rates in ORION-10 and ORION-11 were not statistically different between inclisiran and placebo for most categories, including muscle symptoms (myalgia), liver enzyme elevation, and kidney markers. This contrasts sharply with the statin experience, where myalgia drives significant discontinuation rates, estimated at 5-29% depending on the population studied.

Real-user reports of fatigue, flu-like symptoms, and joint pain do appear on Drugs.com and Reddit, but at low frequency. Because inclisiran works inside the liver cell via RNA interference rather than systemically blocking an enzyme throughout the body, its theoretical side-effect profile is narrower than statins. Whether this translates cleanly into real-world tolerability for every patient is still being studied in post-marketing surveillance.

Liver Safety

Inclisiran acts specifically in hepatocytes (liver cells). Liver enzyme elevations (ALT, AST) occurred at similar rates in treatment and placebo arms in the ORION trials. Still, if you have pre-existing liver disease, your prescriber will want baseline and periodic liver function tests.

Kidney Safety

Because inclisiran is cleared partly by the kidneys, the FDA label notes that no dose adjustment is required in mild-to-moderate chronic kidney disease, but there is limited data in severe renal impairment (eGFR <30 mL/min/1.73 m²). Women with lupus nephritis, diabetic nephropathy, or other causes of reduced kidney function should discuss this specifically with their prescriber.

Women's Physiology: How Sex and Hormones Change the Picture

The Evidence Gap Is Real

Women made up fewer than 40% of participants in ORION-10 and ORION-11. A formal sex-stratified safety analysis has not been published for these trials. This means that nearly everything known about inclisiran's tolerability in women is extrapolated from a majority-male dataset or from subgroup analyses too small to detect meaningful differences. This is not unique to inclisiran; it reflects decades of cardiovascular trial design that enrolled fewer women, but it is a real evidence gap you deserve to know about.

Perimenopause and the LDL Rise

LDL cholesterol tends to rise during perimenopause, an effect driven by declining estrogen's influence on LDL receptor activity in the liver. A longitudinal analysis from the SWAN study found that LDL-C increased by approximately 9 mg/dL across the menopausal transition. For women who already have HeFH or established ASCVD, this perimenopausal LDL surge compounds an already elevated baseline risk.

Inclisiran has not been studied specifically in perimenopausal women or stratified by menopausal status. If you are in your late 40s or early 50s, your LDL trajectory may be rising faster than your prescriber expects, and a twice-yearly drug that takes 3-6 months to reach full effect is a different treatment decision than a daily statin you can up-titrate quickly.

Hormonal Contraceptives and Menopausal Hormone Therapy

No pharmacokinetic interaction study between inclisiran and combined hormonal contraceptives or menopausal estrogen-progestogen therapy has been published. Because inclisiran acts via intracellular RNA interference in hepatocytes rather than through cytochrome P450 enzyme pathways, interaction via the classic CYP3A4 route is not expected. The FDA prescribing information does not list contraceptives or HRT as interacting drugs. Even so, the absence of a dedicated study means this is extrapolated pharmacology, not confirmed in women on combined hormonal therapy.

PCOS, Familial Hypercholesterolemia, and Metabolic Risk

Women with polycystic ovary syndrome (PCOS) have a higher prevalence of dyslipidemia, with studies showing elevated LDL and lower HDL compared with BMI-matched controls. For a woman with PCOS and concurrent HeFH, or with ASCVD risk driven by insulin resistance and elevated non-HDL, inclisiran could be a useful add-on to statin and ezetimibe therapy. No PCOS-specific inclisiran study exists. Any prescribing in this group is off-label in the sense that PCOS itself is not a labeled indication, though high LDL in the context of PCOS can meet the approved indication thresholds.

Pregnancy, Lactation, and Contraception: Required Reading

Leqvio is contraindicated in pregnancy. Stop the drug before attempting conception.

Pregnancy

Inclisiran does not have a formal FDA pregnancy category (post-2015 labeling uses narrative descriptions rather than letter grades). The FDA prescribing information states that animal reproductive studies showed fetal developmental toxicity at doses that produced maternal systemic exposure comparable to the human therapeutic dose. Human pregnancy data are absent because pregnant women were excluded from all ORION trials.

Because inclisiran is dosed only twice yearly, timing matters. The drug has a half-life in plasma of approximately 9 hours but its intracellular effect in liver cells persists for months after plasma clearance. If you are planning a pregnancy, your prescriber needs to weigh whether to withhold the next scheduled dose or to switch you to an alternative LDL-lowering therapy that has a more established safety profile in pregnancy (bile acid sequestrants, for example, have the best safety data in pregnancy among LDL-lowering drugs, though they are not broadly effective for HeFH).

The ACOG guidance on cardiovascular disease and pregnancy does not specifically address inclisiran, as it is too new, but it categorizes lipid-lowering therapy generally as an area requiring individualized benefit-risk discussion in high-risk pregnant women.

Lactation

No human lactation data exist for inclisiran. The FDA label advises against breastfeeding during treatment and for a period after the last dose, given the uncertainty. Because inclisiran is a large-molecule RNA drug, it is unlikely to be absorbed through the infant gut even if present in breast milk, but the lack of data means the precautionary recommendation stands. If you are postpartum and breastfeeding and need LDL-lowering treatment, discuss bile acid sequestrants with your cardiologist as a temporary option.

Contraception Requirement

Women of reproductive potential should use effective contraception while receiving inclisiran. The twice-yearly dosing means that simply stopping the drug does not rapidly clear the pharmacodynamic effect; plan ahead with your prescriber if you are approaching a planned pregnancy.

Who This Drug Is Right For (And Who Should Wait)

Good Candidates by Life Stage

Reproductive years (not planning pregnancy): Women with HeFH or ASCVD who have not reached LDL targets on maximally tolerated statin plus ezetimibe are appropriate candidates. Use effective contraception. Confirm hormonal medication list with your prescriber before starting.

Perimenopause: If your LDL is rising as you approach menopause and you have established cardiovascular disease or HeFH, inclisiran is an evidence-based add-on. Acknowledge that perimenopausal LDL trajectories may require more frequent monitoring of your response.

Postmenopause: The indication does not change. Postmenopausal women with HeFH or ASCVD who cannot reach guideline LDL targets are a core population for this drug. Access and insurance coverage remain the practical barriers, not physiology.

Women with PCOS and very high LDL: Discuss with your cardiologist and endocrinologist. No dedicated data, but the lipid indication can apply.

Who Should Not Use Inclisiran Right Now

• Pregnant women or those planning conception in the near term.
• Breastfeeding women (precautionary based on absent data).
• Women with severe hepatic impairment (Child-Pugh C); pharmacokinetics are unstudied in this group.
• Women whose LDL has not been adequately worked up; inclisiran is not a first-line drug. ACC/AHA guidelines position PCSK9 inhibitors as add-on therapy after statin and ezetimibe.

Leqvio vs. PCSK9 Monoclonal Antibodies: A Quick Women's-Health Comparison

Evolocumab (Repatha) and alirocumab (Praluent) are biologic PCSK9 inhibitors that work by a different mechanism (antibody-based) but achieve similar LDL reductions, roughly 50-60% from baseline. They are self-injected every 2 or 4 weeks. Inclisiran's twice-yearly clinic dosing appeals to women who prefer not to self-inject, but it removes the flexibility to pause quickly if pregnancy is planned.

Monoclonal antibody PCSK9 inhibitors also have limited pregnancy data but slightly more real-world experience because they have been on the market longer. For a woman actively planning a family, the shorter-acting monoclonal antibody option may allow a shorter washout window, though neither is formally approved for use in pregnancy.

Practical Advice for Women Starting Leqvio

1. Get a baseline lipid panel, liver function tests, and a kidney function panel (eGFR, creatinine) before your first injection.
2. Tell every provider on your team, including your OB-GYN or women's-health NP, that you are starting inclisiran.
3. Confirm your contraception plan if you are premenopausal and not currently pregnant.
4. Schedule your first follow-up lipid panel at approximately 90 days after the first injection to verify response before the second dose.
5. Document the injection-site location. Rotating between upper arm and thigh can reduce cumulative local irritation.
6. Ask your cardiologist whether ORION-4 results, expected around 2026, will change the risk-benefit conversation for your specific situation.

What Does "Real Results" Actually Mean for Your LDL Number?

The 50% reduction figure from ORION-10 and ORION-11 is a mean. Your individual result will depend on your baseline LDL, whether you are on background statin therapy, and your LDLR (LDL receptor) gene variant if you have HeFH. Women with loss-of-function LDLR mutations (as opposed to APOB or PCSK9-gain-of-function mutations) may see a somewhat smaller absolute response to inclisiran because the drug works by increasing LDL receptor expression; if you have almost no functional LDL receptors, that pathway is limited. Ask your genetic counselor or lipidologist whether your mutation type predicts response.

In practical terms: if your LDL is 180 mg/dL on a statin and ezetimibe, a 50% reduction brings you to 90 mg/dL. If your target is <55 mg/dL (the ESC 2021 very-high-risk target), you may still fall short. That calculation is worth doing with your cardiologist before starting, so expectations are calibrated.